title: Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
abstract: BACKGROUND
  This study involved 300 Pseudomonas aeruginosa strains isolated from patients admitted in four Tehran hospitals. Using standard O-specific typing sera, they were all grouped into 16 strains out of 17 known P. aeruginosa. The strains were lyophilized and each was given a code according to the Collection of Standard Bacteria, Pasteur Institute of Iran (CSBPI) for further investigations.
  
  
  METHODS
  Among all clinical samples, CSBPI: 16-190 was the most prevalent P. aeruginosa serotype which showed a high agglutination titer (4+, 320) against homologous O-specific typing sera. This serotype was selected for extraction of P. aeruginosa major outer membrane vesicles (OMP-F). OMP-F vesicles were extracted and purified according to the Deoxycholate Ultracentrifuge Differentiation Technique. Purity and molecular weight of OMP-F were determined by SDS-PAGE and the ability of OMP-F vesicles to induce high titers of antibody in rabbit, which was shown as a sharp antibody-antigen precipitation line in the agarose gel immune-diffusion technique.
  
  
  RESULTS
  Passive immunization of mice with anti-rabbit OMP-F antisera induced a high level of protection when the mice were post-challenged with 2×LD50 of live P. aeruginosa CSBPI: 16-190. Furthermore, active immunization of mice with 50 µg of OMP-F could protect mice against 2xLD50 of live homologous (100% protection) and 15 heterologous native Iranian P. aeruginosa serotypes with 50-100% level of protection.
  
  
  CONCLUSIONS
  These investigations indicate that purified OMP-F of CSBPI: 16-190 can be regarded as a safe protective immunogen in vaccinothrapy against all P. aeruginosa immunotype isolated in Iran.
authors.affiliation: Department of Bacterial Vaccines and Antigens Production, Pasteur Institute of Iran, Tehran, Iran. Hojiahmadi@yahoo.com
authors.forename: Hojat
authors.initials: H
authors.lastname: Ahmadi
authors.forename: Bahman
authors.initials: B
authors.lastname: Tabaraie
authors.forename: Shayan
authors.initials: S
authors.lastname: Maleknia
authors.forename: Farahnaz
authors.initials: F
authors.lastname: Pormirzagholi
authors.forename: Mehdi
authors.initials: M
authors.lastname: Nejati
authors.forename: Mohammad Hosein
authors.initials: MH
authors.lastname: Hedayati
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D007492:Iran / Q000453:epidemiology; D051379:Mice; D018272:Porins / Q000276:immunology* / Q000302:isolation & purification; D011552:Pseudomonas Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D054406:Pseudomonas Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011550:Pseudomonas aeruginosa / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D011817:Rabbits; D022142:Secretory Vesicles / Q000276:immunology; D012703:Serotyping; D016019:Survival Analysis; D014611:Vaccination / Q000379:methods
chemical_list: D000907:Antibodies, Bacterial; C109237:OmpF protein; D018272:Porins; D054406:Pseudomonas Vaccines